WNTinib

N/A

Report date: 2025/03/20 09:55:57
NME

Base Information

Drug NameWNTinib
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A inhibitorsHistone-lysine N-methyltransferase EZH2 modulators
TargetsNerve growth factor receptor Trk-AHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsLiver NeoplasmsHepatoblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIcahn School Of Medicine At Mount Sinai
China Registration ClassN/A

Develop Information

Active CompaniesIcahn School Of Medicine At Mount Sinai
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsHepatoblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A